Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

G2295

Sigma-Aldrich

Glimepiride

≥98% (HPLC), solid

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C24H34N4O5S
Numero CAS:
93479-97-1
Peso molecolare:
490.62
Numero MDL:
MFCD00878417
Codice UNSPSC:
12352200
ID PubChem:
24895093
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

solid

Colore

white

Punto di fusione

212.2-214.5 °C

Solubilità

DMSO: >10 mg/mL

Ideatore

Sanofi Aventis

Temperatura di conservazione

room temp

Stringa SMILE

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
WIGIZIANZCJQQY-RUCARUNLSA-N

Informazioni sul gene

human ... ABCC8(6833) , KCNJ1(3758) , KCNJ11(3767)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Glimepiride is a class II biopharmaceutical second-generation sulfonylurea.

Applicazioni

Glimepiride has been used:
  • as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)
  • as a sulfonylurea ATP-sensitive potassium channel (KATP) channel inhibitor in breast cancer MDA-MB-231 cells
  • in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion

Glimepiride is currently used to treat type 2 diabetes.

Azioni biochim/fisiol

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.
Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.

Caratteristiche e vantaggi

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazard
GHS08

Avvertenze

Warning

Indicazioni di pericolo

H361

Classi di pericolo

Repr. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
075M4753V
013M4715V
101M4733V
050M47111
050M4711

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

Nateglinide ≥98% (HPLC), solid

Sigma-Aldrich

N3538

Nateglinide

Glimepiride for system suitability European Pharmacopoeia (EP) Reference Standard

Y0000516

Glimepiride for system suitability

Gliclazide British Pharmacopoeia (BP) Reference Standard

BP368

Gliclazide

USP

USP

1292347

Glimepiride Related Compound D

vibrant-m

Y0001742

Glimepiride for impurity A identification

Gliclazide European Pharmacopoeia (EP) Reference Standard

G0326000

Gliclazide

Glipizide European Pharmacopoeia (EP) Reference Standard

G0340000

Glipizide

Glibenclamide ≥99% (HPLC)

Sigma-Aldrich

G0639

Glibenclamide

USP

USP

1292336

Glimepiride Related Compound C

Li-Ping Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)
By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This
A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG
Tiwari A, et al.
International Journal of Advanced Research , 4, 920-927 (2016)
W Rathmann et al.
Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)
To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;
Lan Gao et al.
International journal of technology assessment in health care, 28(4), 436-444 (2012-09-26)
The aim of this study was to evaluate the long-term cost-utility of liraglutide versus glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted in Asian population. The
William T Cefalu et al.
Lancet (London, England), 382(9896), 941-950 (2013-07-16)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with
Visualizza tutti i documenti correlati

Articoli

Insulin Signaling and Energy Homeostasis

Glucose metabolism is regulated by the opposing actions of insulin and glucagon. Insulin is released from pancreatic ß cells in response to high blood glucose levels and regulates glucose metabolism through its actions on muscle, liver, and adipose tissue.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.